ASCO Direct Highlights | Conference

New and Updated Findings Showcase a Shift With Immunotherapy Across Melanoma

August 16th 2021

Data that emerged from the 2021 ASCO Annual Meeting represent potential paradigm shifts for patients with advanced melanoma.

Immunotherapy, Targeted Therapy, and Novel Strategies Progress Practice in GI Malignancies

August 9th 2021

Data that were presented during the 2021 ASCO Annual Meeting shed light on new therapeutic strategies, and treatment considerations that are expanding the paradigms of gastrointestinal malignancies.

ASCO 2021 Delivers Personalized Treatment Approaches Across Breast Cancer

August 6th 2021

Refining treatment is not only a key aim of research in breast cancer but a greater possibility in the clinic with neoadjuvant and adjuvant PARP inhibitors, HER2 monoclonal antibodies, and greater stratification of genomic risk.

IDH1 Inhibitors, CAR T-Cell Therapy, and Third-Generation TKIs Refresh Relapsed/Refractory Leukemia Landscape

August 4th 2021

The novel agents olutasidenib, brexucabtagene autoleucel, and ponatinib demonstrated encouraging data at the 2021 ASCO Annual Meeting in leukemias, renewing hope in the ability to salvage patients with relapsed/refractory disease.

KRAS Inhibitors, Immunotherapy, and ADCs Carve Out Newfound Applications in NSCLC

August 3rd 2021

The 2021 ASCO Annual Meeting was chock full of practice-changing, practice-affirming, and exciting preliminary research in non–small cell lung cancer, said Melissa Johnson, MD.

Pal Provides Perspective on Pivotal Trials in RCC and Prostate Cancer

July 27th 2021

Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.

Siddiqi Spotlights Latest Data on Optimization of Therapy in Hematologic Malignancies

July 23rd 2021

Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.

Usmani Underscores New and Updated Data Across Myeloma Paradigm

July 9th 2021

Although the armamentarium of multiple myeloma is rich with available treatment options, novel triplet regimens, maintenance therapies, and targets beyond BCMA are further expanding the paradigm across the newly diagnosed, early-relapse, and late-relapse disease states.

ASCO 2021 Brings Increasing Recognition of Health Disparities in Cancer Care

July 8th 2021

Several studies presented during the 2021 ASCO Annual Meeting highlighted the severity of racial and ethnic disparities that exist in the treatment of patients with cancer, ranging from clinical trial enrollment to routine care visits.

Coleman Centers the Discussion on Practice-Affirming ASCO Trials in Gynecologic Oncology

June 29th 2021

Practice-validating trials in cervical cancer, endometrial cancer, and ovarian cancer were the focus of the 2021 ASCO Annual Meeting in gynecologic oncology, each carrying relevant implications on extended therapy, surveillance, and biomarker testing.

Carving Out New Combination Therapies in Stem Cell Disorders

July 13th 2020

Despite the influx of novel agents that have received regulatory approval in recent years in stem cell disorders, there is still room for improvement.

Rini Reviews Key ASCO 2020 Highlights in Genitourinary Cancers

July 13th 2020

As part of the 2020 ASCO Direct Highlights™ webcast, Brian Rini, MD, discusses key developments in genitourinary cancers that were presented during the 2020 ASCO Virtual Scientific Program.

Postow Presents Progress Made in Melanoma

July 10th 2020

Immunotherapy and BRAF plus MEK inhibition are the key players in the treatment of patients with melanoma, Michael Postow, MD, said in a presentation during the 2020 ASCO Direct Highlights webcast.

Singal Speaks to ASCO Highlights in Rapidly Evolving HCC Paradigm

July 10th 2020

The treatment landscape of advanced hepatocellular carcinoma has been subject to rapid development in the last few years, says Amit G. Singal, MD, MS.

ASCO 2020 Heralds a Handful of Influential Data Across Breast Cancer Settings

July 10th 2020

The 2020 ASCO Virtual Scientific Program delivered a number of important updates to the field of breast cancer, explained Joyce A. O'Shaughnessy, MD.

ASCO 2020 Delivers Growing Insights on Supportive Care, Genetic Testing, and Symptom Management

June 30th 2020

Dawn L. Hershman, MD, MS, spotlights important data pertaining to cancer care delivery, prevention, symptom management, and survivorship that were presented at the 2020 ASCO Virtual Scientific Program.

Leonard Leads Discussion on Latest Developments in Leukemias and Lymphomas

June 26th 2020

Data in Richter’s transformation, Hodgkin lymphoma, Waldenström macroglobulinemia, and indolent lymphoma were presented at the 2020 ASCO Virtual Scientific Program, and although not entirely practice changing, are deserving of attention.

Brown Spotlights Key ASCO Highlights in Gynecologic Malignancies

June 26th 2020

The field of gynecologic oncology gained a number of important updates at the 2020 ASCO Virtual Scientific Program. As part of the ASCO Direct Highlights webcast, Jubilee Brown, MD, provided insight on key trials that were presented at the program.

Contemporary Considerations for Cancer Care in the COVID-19 Era

June 26th 2020

The downstream effects of the coronavirus disease 2019 on patients with cancer have become apparent over the past few months, and the onus is on the field to provide clinical guidance on best practices in the absence of definitive data.

Multiple Myeloma Paradigm Moves Forward With Promising Portfolio

June 25th 2020

There was no shortage of exciting developments at the 2020 ASCO Virtual Scientific Program in multiple myeloma. Peter Voorhees, MD, explained all of the pivotal data in myeloma therapeutics in a virtual presentation during the 2020 ASCO Direct Highlights webcast.